Clarivate Plc
GBFinancials
Valuation Metrics
Clarivate Plc's Market Cap is $1.07B. At end of 2025 it was $2.19B. Ranked #2387 of 3,118 in US market (top 77%), #1421 of 1,644 on NYSE (top 86%), #226 of 271 in Software & Services (top 83%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $1.07B | US#2,387/3,118 Sec#226/271 |
| Revenue | $2.41B | US#1,323/3,118 Sec#101/271 |
| Net Income | $-334M | US—/3,118 Sec—/271 |
| Total Assets | $10.49B | US#959/3,118 Sec#59/271 |
| Net Assets | $4.54B | US#744/3,118 Sec#44/271 |
| Employees | 12,000 | US#776/3,118 Sec#56/271 |
| Value | ||
| P/B | 0.24x | US#25/3,118 Sec#1/271 |
| P/S | 0.44x | US#277/3,118 Sec#23/271 |
| EV/EBITDA | 10.63x | US#910/3,118 Sec#48/271 |
| FCF Yield | 30.69% | US#85/3,118 Sec#11/271 |
| Profitability | ||
| ROE | -7.36% | US#2,309/3,118 Sec#193/271 |
| ROA | -3.19% | US#2,447/3,118 Sec#211/271 |
| Op. Margin | -3.51% | US#2,422/3,118 Sec#212/271 |
| Revenue Growth | -3.50% | US#2,378/3,118 Sec#248/271 |
| Financial Health | ||
| Debt Ratio | 131.10% | US#1,351/3,118 Sec#127/271 |
| Total Debt | $4.26B | US#754/3,118 Sec#42/271 |
| FCF | $328M | US#1,105/3,118 Sec#107/271 |
| Cash | $218M | US#1,672/3,118 Sec#177/271 |
| Current Ratio | 0.85x | US#2,438/3,118 Sec#241/271 |
| Net Debt/EBITDA | 8.41x | US#2,317/3,118 Sec#213/271 |
| Performance | ||
| 1Y Return | -50.88% | US#2,860/3,118 Sec#238/271 |
| 1M Return | 12.84% | US#1,944/3,118 Sec#194/271 |
| From 52W High | -56.85% | US#2,792/3,118 Sec#243/271 |
| 1Y MDD | -61.44% | US#2,757/3,118 Sec#219/271 |
| Trading | ||
| Volume | 3,368,374 shares | US#607/3,118 Sec#78/271 |
| Trading Value | $6M | US#2,572/3,118 Sec#236/271 |
| Per Share | ||
| EPS | $-0.52 | US—/3,118 Sec—/271 |
| BPS | $7.10 | US#2,074/3,118 Sec#127/271 |
Company Info
Clarivate Plc operates as a prominent information services and analytics firm, furnishing structured data and insights. Its core mission is to facilitate the discovery, safeguard the intellectual property, and enable the commercialization of scientific research, innovations, and established brands. The company's portfolio includes the extensive Web of Science suite, a collection of essential tools such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio. These are designed to support organizations throughout the entire research lifecycle, from initial planning and funding to execution and utilization. Within the Life Sciences domain, Clarivate provides specialized products like Cortellis and Newport Integrity. These platforms cater to pharmaceutical and biotechnology companies, empowering their research endeavors, supplying vital market intelligence, and facilitating competitive monitoring during the development and launch phases of novel drugs. Its Derwent product line, comprising Derwent Innovation, Techstreet, and IP Professional Services, is dedicated to intellectual property management. These tools enable customers to evaluate the originality of potential products, establish their freedom to operate within design parameters, secure patent protection, analyze the competitive technological landscape, and ensure adherence to essential industry standards. Complementing these, CompuMark delivers trademark screening, search, and monitoring solutions vital for businesses and legal firms. Meanwhile, MarkMonitor empowers enterprises to establish, manage, optimize, and fortify their digital presence. Clarivate's diverse clientele spans government agencies, academic institutions, life science enterprises, and research and development corporations worldwide, with operations across the Americas, Middle East, Africa, Europe, and Asia Pacific regions. The company, initially known as Clarivate Analytics Plc, rebranded to Clarivate Plc in May 2020. It maintains its headquarters in London, United Kingdom.